Kawasaki disease: An overview

Current Opinion in Infectious Diseases

Volumn 21, Issue 3, 2008, Pages 263-270

  Pinna, Georgia S ^a   Kafetzis, Dimitris A ^b,d   Tselkas, Orestis I ^c   Skevaki, Chrysanthi L ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^d P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

Author keywords

Aspirin; Coronary artery aneurysm; Corticosteroids; Diagnostic criteria; Intravenous immunoglobulin; Kawasaki disease; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISONE; TICLOPIDINE; ULINASTATIN; WARFARIN;

ANGIOGRAPHY; BLOOD VISCOSITY; BYPASS SURGERY; CHILL; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ANEURYSM; DISEASE ASSOCIATION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEVER; GENETIC PREDISPOSITION; HEALTH HAZARD; HEART DISEASE; HEART INFARCTION; HUMAN; HYPOTENSION; INCIDENCE; LABORATORY TEST; LONG TERM CARE; MONOTHERAPY; MORBIDITY; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMAPHERESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; STENOSIS; STENT; THROMBOEMBOLISM; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ASPIRIN; CHILD, PRESCHOOL; HEART DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 42949159757     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282fbf9cd     Document Type: Review

References (95)

1. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr 2004; 16:508-514.
2. Bhatt M, Anil SR, Sivakumar K, Kumar K. Neonatal Kawasaki Disease. Indian J Pediatr 2004; 71:353-354. (abstract).
3. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on rheumatic fever, endocarditis, and Kawasaki disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114:1708-1733.2
4. Park YW, Han JW, Park IS, et al. Epidemiologic picture of Kawasaki disease in Korea, 2000-2002. Pediatr Int 2005; 47:382-387. (abstract).
5. Chang LY, Chang IS, Lu CY, et al., Kawasaki Disease Research Group. Epidemiologic features of Kawasaki Disease in Taiwan, 1996-2002. Pediatrics 2004; 114:678-682.
6. Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome in Hawaii. Pediatr Infect Dis J 2005; 24:429-433.
7. Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364:533-544.
8. Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191:499-502.
9. Wang X, Zhang G, Liu F, et al. Prevalence of human parvovirus B19 DNA in cardiac tissues of patients with congenital heart diseases indicated by nested PCR and in situ hybridization. J Clin Virol 2004; 31:20-24.
10. Catalano-Pons C, Giraud C, Rozenberg F, et al. Detection of human bocavirus in children with Kawasaki disease. Clin Microbiol Infect 2007. [Epub ahead of print] A novelty regarding the etiology of the disease that remains an area of research.
11. Usta GB, Cengiz N, Yildirim SV, Uslu Y. Cytomegalovirus infection in a patient with atypical Kawasaki disease. Rheumatol Int 2007. [Epub ahead of print]
12. Chou CT, Chang JS, Ooi SE, et al. Serum anti-Yresinia antibody in Chinese patients with Kawasaki disease. Arch Med Res 2005; 36:14-18.
13. Matsubara K, Fukaya T. The role of superantigens of group A Streptococcus and Staphylococcus aureus in Kawasaki disease. Curr Opin Infect Dis 2007; 20:298-303. A comprehensive review that summarizes recent publications concerning the role of bacterial superantigens and their contribution to the etiology of Kawasaki disease, a major issue that still invites contention.
14. Leung DYM. Superantigens related to Kawasaki Syndrome. Springer Semin Immunopathol 1996; 17:385-396.
15. Leung DY, Meissner HC, Shulman ST, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki Disease. J Pediatr 2002; 140:742-746.
16. Gupta-Malhotra M, Viteri-Jackson A, Thomas W, Zabriskie JB. Antibodies to highly conserved peptide sequence of staphylococcal and streptococcal superantigens in Kawasaki disease. Exp Mol Pathol 2004; 76:117-121.
17. Rowley AH, Shulman ST, Spike BT, et al. Oligoclonal IgA response in the vascular wall in acute Kawasaki Disease. J Immunol 2001; 166:1334-1343.
18. Caquard M, Parlier G, Siret D. Family observation of Kawasaki disease: 2 cases in sister and brother. Arch Pediatr 2006; 13:453-455.
19. Harada F, Sada M, Kamiya T, et al. Genetic analysis of Kawasaki syndrome. Am J Hum Genet 1986; 39:537-539.
20. Burns JC, Shimizu C, Shike H, et al. Candidate genes for susceptibility to Kawasaki disease (KD): analysis of preferentially transmitted alleles in patient/parent triads. Pediatr Res 2003; 53:1857A. (abstract).
21. Burns JC, Shimizu C, Gonzalez E, et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki Disease. J Infect Dis 2005; 192:344-349.
22. Yang J, Li CR, Li YB, et al. Correlation between mannose-binding lectin gene codon 54 polymorphism and susceptibility of Kawasaki disease. Zhonghua Er Ke Za Zhi 2004; 42:176-179. (abstract).
23. Wu SF, Chang JS, Wan L, et al. Association of IL-1Ra gene polymorphism, but no association of IL-1beta and IL-4 gene polymorphisms, with Kawasaki disease. J Clin Lab Anal 2005; 19:99-102. (abstract).
24. Ahn SY, Jang GC, Shin JS, et al. Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea. Yonsei Med J 2003; 44:1021-1026. (abstract).
25. Furuno K, Yuge T, Kusuhara K, et al. CD25+ CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr 2004; 145:385-390. (abstract).
26. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008; 40:35-42.
27. Wu CY, Hsieh KS, Chiou YH, et al. Prolonged fever and pyuria: a urinary tract infection presentation of incomplete Kawasaki disease. Acta Paediatr 2005; 94:375-377.
28. Chang CH, Chen MH, Yang W. Kawasaki disease presenting with lymphadenopathy and gastrointestinal hemorrhage: report of one case. Acta Paediatr Taiwan 2004; 45:171-173.
29. Madhok AB, Boxer R, Green S. An adolescent with chest pain-sequela of Kawasaki disease. Pediatr Emerg Care 2004; 20:765-768.
30. Marchetto S, Chiappini E, Simonini G, et al. Lupus-like onset of recurrent Kawasaki disease in an adolescent boy. Clin Exp Rheumatol 2004; 22:377.
31. Sengler C, Gaedicke G, Wahn U, Keitzer R. Pulmonary symptoms in Kawasaki disease. Pediatr Infect Dis J 2004; 23:782-784.
32. Duzova A, Topaloglu R, Keskin M, et al. An unusual pattern of arthritis in a child with Kawasaki syndrome. Clin Rheumatol 2004; 23:73-75.
33. Watanabe T, Iwabuchi H, Abe T. Rhabdomyolysis in a patient with Kawasaki disease. Eur J Pediatr 2003; 162:891-892.
34. Chen WT, Huang SR, Wang JK. Kawasaki disease presenting with hepatitis and prolonged fever: report of one case. Acta Paediatr Taiwan 2003; 44:174-176.
35. Miura M, Mochizuki T, Fukushima H, Ishihara J. A case of Kawasaki disease accompanied by Henoch-Schonlein purpura. Clin Exp Rheumatol 2004; 22:377-378.
36. Lee KY, Han JW, Hong JH, et al. Inflammatory processes in Kawasaki disease reach their peak at the sixth day of fever onset: laboratory profiles according to duration of fever. J Korean Med Sci 2004; 19:501-504.
37. Mekmullica J, Pancharoen C, Deerojanawong J, et al. Concomitant dengue infection and Kawasaki disease in an infant: a case report and literature review. J Med Assoc Thai 2005; 88:436-439.
38. Wong D, Nutting A, Yeung RS, McCrindle BW. Kawasaki disease and scald injuries: a possible association. Can J Cardiol 2004; 20:1147-1149.
39. Anderson MS, Todd JK, Glode MP. Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. Pediatrics 2005; 115:428-433. (abstract).
40. Minich LL, Sleeper LA, Atz AM, et al. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics 2007; 120:1434-1440.
41. Miron D, Fink D, Hashkes PJ. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. Clin Rheumatol 2003; 22:461-463.
42. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003; 112 (6 Pt 1):e495.
43. Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003; 22:663-666.
44. Mine K, Takaya J, Hasui M, et al. A case of Kawasaki disease associated with syndrome of inappropriate secretion of antidiuretic hormone. Acta Paediatr 2004; 93:1547-1549.
45. Dalla Pozza R, Bechtold S, Urschel S, et al. Subclinical atherosclerosis, but normal autonomic function after Kawasaki disease. J Pediatr 2007; 151:239-243.
46. Okada Y, Minakami H, Tomomasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 2004; 48:199-205.
47. Nomura Y, Masuda K, Maeno N, et al. Serum levels of interleukin-18 are elevated in the subacute phase of Kawasaki syndrome. Int Arch Allergy Immunol 2004; 135:161-165.
48. Mitani Y, Sawada H, Hayakawa H, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005; 111:38-43.
49. Popper SJ, Shimizu C, Shike H, et al. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol 2007; 8:R261.
50. Biezeveld MH, van Mierlo G, Lutter R, et al. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. Clin Exp Immunol 2005; 141:183-188.
51. Gupta-Malhotra M, Levine DM, Cooper RS, Zabriskie JB. Decreased levels of cystatin C, an inhibitor of the elastolytic enzyme cysteine protease, in acute and subacute phases of Kawasaki disease. Cardiology 2003; 99:121-125.
52. Jibiki T, Terai M, Kohno Y. High concentrations of interleukin-8 and monocyte chemoattractant protein-1 in urine of patients with acute Kawasaki disease. Eur J Pediatr 2004; 163:749-750.
53. Wong D, Harder J, Jadavji T. Kawasaki disease, myocardial infarction and coronary artery revascularization. Can J Cardiol 2005; 21:601-604.
54. Miyashita M, Karasawa K, Taniguchi K, et al. Usefulness of real-time 3-dimensional echocardiography for the evaluation of coronary artery morphology in patients with Kawasaki disease. J Am Soc Echocardiogr 2007; 20:930-933. A current evaluation of a traditional diagnostic tool for Kawasaki disease.
55. Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004; 46:33-38.
56. Takeshita S, Kawamura Y, Takabayashi H, et al. Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clin Exp Immunol 2005; 139:575-579.
57. Fukazawa R, Sonobe T, Hamamoto K, et al. Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease. Pediatr Res 2004; 56:597-601.
58. Ye F, Foell D, Hirono KI, et al. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. Am J Cardiol 2004; 94:840-844.
59. Guzman-Cottrill JA, Garcia FL, Shulman ST, Rowley AH. CD8 T lymphocytes do not express cytotoxic proteins in coronary artery aneurysms in acute Kawasaki disease. Pediatr Infect Dis J 2005; 24:382-384.
60. Lin MT, Tsao LY, Cheng ML, et al. Absence of hypercoagulability in acute Kawasaki disease. Pediatr Int 2005; 47:126-131.
61. Nomura I, Abe J, Noma S, et al. Adrenomedullin is highly expressed in blood monocytes associated with acute Kawasaki disease: a microarray gene expression study. Pediatr Res 2005; 57:49-55.
62. Mavrogeni S, Papadopoulos G, Douskou M, et al. Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol 2004; 43:649-652.
63. Sohn S, Kim HS, Lee SW. Multidetector row computed tomography for follow-up of patients with coronary artery aneurysms due to Kawasaki disease. Pediatr Cardiol 2004; 25:35-39.
64. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004; 6:203-211.
65. Dajani AS, Taubert KA, Takahashi M, et al. Guidelines for long-term management of patients with Kawasaki disease: report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994; 89:916-922.
66. Kaul S, Ito H. Microvasculature in acute myocardial ischemia: Part I. Evolving concepts in pathophysiology, diagnosis, and treatment. Circulation 2004; 109:146-149.
67. Lim CW, Ho KT, Quek SC. Exercise myocardial perfusion stress testing in children with Kawasaki disease. J Paediatr Child Health 2006; 42:419-422.
68. Burns JC. Kawasaki disease. N Engl J Med 2007; 356:659-661. A very interesting evaluation of the imaging methods available nowadays for the estimation of children with Kawasaki disease.
69. Tse SML, Silverman ED, McGrindle BW, Yeung RSM. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002; 140:450-455.
70. Wilson N, Heaton P, Calder L, et al. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience. J Paediatr Child Health 2004; 40:524-529.
71. Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008. [Epub ahead of print]
72. Fong NC, Hui YW, Li CK, Chiu MC. Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr Cardiol 2004; 25:31-34.
73. Lee KY, Lee HS, Hong JH, et al. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki disease. J Trop Pediatr 2005; 51:98-101.
74. Abe J, Jibiki T, Noma S, et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005; 174:5837-5845.
75. Sugita K, Hirao J, Arisaka O, Eguchi M. Gamma-globulin-induced modulation with necrotic-like morphology of peripheral blood neutrophils. Eur J Pharmacol 2005; 513:141-144.
76. Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002; 86:286-290.
77. Baba R, Shibata A, Tsurusawa M. Single high-dose intravenous immunoglobulin therapy for Kawasaki disease increases plasma viscosity. Circ J 2005; 69:962-964.
78. Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol 2005; 34:136-139.
79. Al Mayouf SM. The use of corticosteroid therapy in refractory Kawasaki patients. Clin Rheumatol 2004; 23:11-13.
80. Lucron H, Bosser G, Lethor JP, et al. Kawasaki disease in newborns and infants: refractory forms to immunoglobulin therapy. Arch Mal Coeur Vaiss 2004; 97:522-528.
81. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004; 163:263-264.
82. Hsieh KS, Weng KP, Lin CC, et al. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004; 114:689-693.
83. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997; 131:888-893.
84. Miura M, Ohki H, Tsuchihashi T, et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 2004; 89:776-780.
85. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 123:146-149.
86. Mori M, Tomono N, Yokota S. Coronary arteritis of Kawasaki disease unresponsive to high-dose intravenous gammaglobulin successfully treated with plasmapheresis. Nihon Rinsho Meneki Gakkai Kaishi 1995; 18:282-288.
87. Iwashima S, Seguchi M, Matubayashi T, Ohzeki T. Ulinastatin therapy in Kawasaki disease. Clin Drug Invest 2007; 27:691-696. A new approach to the treatment of Kawasaki disease.
88. O'Brien M, Parness IA, Neufeld EJ, et al. Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. Pediatrics 2000; 105:e64.
89. Williams RV, Wilke VM, Tani LY, Minich LL. Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002; 109:e4.
90. Subcommittee of Surgical Treatment, Kawasaki Disease Research Committee. Guidelines for treatment and management of cardiovascular in Kawasaki disease. Subcommittee of Cardiovascular Sequelae. Heart Vessels 1987; 3:50-54.
91. Kitamura S, Kameda Y, Seki T, et al. Long-term outcome of myocardial revascularization in patients with Kawasaki coronary artery disease. J Thorac Cardiovasc Surg 1994; 107:663-674.
92. Hwong TM, Arifi AA, Wan IY, et al. Rupture of a giant coronary artery aneurysm due to Kawasaki disease. Ann Thorac Surg 2004; 78:693-695.
93. Ishii M, Ueno T, Akagi T, et al. Guidelines for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr Int 2001; 43:558-562.
94. Ogawa S, Ohkubo T, Fukazawa R. Estimation of myocardial hemodynamics before and after intervention in children with Kawasaki disease. J Am Coll Cardiol 2004; 43:653-661.
95. Lee JY, Song JY, Kim SJ, et al. Coronary rotational ablation for calcific coronary artery stenosis in a young child. Int J Cardiol 2005; 99:349-350.